Insider · CIK 0001786322
Giuseppe Ciaramella
presidentofficer
Files at BEAM (Beam Therapeutics Inc.). First filing Oct 16, 2024, latest Feb 26, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $3.9M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BEAM: Beam Therapeutics Inc.
BEAMOct 9, 2026 · close 25.70
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Beam Therapeutics Inc. | $1.1M 35,000 shares | -16% | +122% from low-9% from high | |
| 26Weak | Beam Therapeutics Inc. | $136k 7,434 shares | -4% | 0% from low-48% from high | |
| 35Weak | Beam Therapeutics Inc. | $1.3M 51,110 shares | -32% | - | |
| 15Weak | Beam Therapeutics Inc. | $1.3M 51,110 shares | -24% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | BEAM Beam Therapeutics Inc. | GGift Common Stock | -123,407 | $0.00 | $0 | 130,504 | 17 d ago |
| Feb 24, 2026 | BEAM Beam Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +35,000 | $17.00 | $595k | 225,216 | Feb 26, 2026 |
| Feb 24, 2026 | BEAM Beam Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -35,000 | $32.00 | $1.1M | 190,216 | Feb 26, 2026 |
| Feb 24, 2026 | BEAM Beam Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -35,000 | $0.00 | $0 | 397,313 | Feb 26, 2026 |
| Jan 31, 2026 | BEAM Beam Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Feb 2, 2026 |
| Apr 1, 2025 | BEAM Beam Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -7,434 | $18.35 | $136k | 190,216 | Apr 3, 2025 |
| Mar 31, 2025 | BEAM Beam Therapeutics Inc. | AGrant or award Common Stock | +35,000 | $0.00 | $0 | 197,650 | Apr 2, 2025 |
| Jan 31, 2025 | BEAM Beam Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Feb 3, 2025 |
| Dec 17, 2024 | BEAM Beam Therapeutics Inc. | MOption exercise Common Stock | +53,500 | $0.67 | $36k | 162,650 | Dec 19, 2024 |
| Dec 17, 2024 | BEAM Beam Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative | -53,500 | $0.00 | $0 | 6,505 | Dec 19, 2024 |
| Nov 6, 2024 | BEAM Beam Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -51,110 | $26.36 | $1.3M | 109,150 | Nov 8, 2024 |
| Oct 14, 2024 | BEAM Beam Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +27,318 | $0.67 | $18k | 196,934 | Oct 16, 2024 |
| Oct 14, 2024 | BEAM Beam Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +12,979 | $4.22 | $55k | 209,913 | Oct 16, 2024 |
| Oct 14, 2024 | BEAM Beam Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +1,457 | $7.22 | $11k | 211,370 | Oct 16, 2024 |
| Oct 14, 2024 | BEAM Beam Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -51,110 | $26.27 | $1.3M | 160,260 | Oct 16, 2024 |
| Oct 14, 2024 | BEAM Beam Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,318 | $0.00 | $0 | 0 | Oct 16, 2024 |
| Oct 14, 2024 | BEAM Beam Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,979 | $0.00 | $0 | 0 | Oct 16, 2024 |
| Oct 14, 2024 | BEAM Beam Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,457 | $0.00 | $0 | 0 | Oct 16, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.